Back to Search Start Over

Albumin-biomineralized nanoparticles to synergize phototherapy and immunotherapy against melanoma.

Authors :
Zhu, Yining
Xue, Jiao
Chen, Wenfei
Bai, Shuting
Zheng, Tao
He, Chunting
Guo, Zhaofei
Jiang, Min
Du, Guangsheng
Sun, Xun
Source :
Journal of Controlled Release. Jun2020, Vol. 322, p300-311. 12p.
Publication Year :
2020

Abstract

To date, cancer phototherapy remains as an unsatisfactory method of cancer treatment due to the high probability of cancer recurrence - an effect that is partly driven by tumor-driven immunosuppression. Therefore, we propose inducing adequate immune responses after photo tumor ablation may be critical to achieve a long term therapeutic effect of phototherapy. Here, we engineered the photosensitizer chlorin e6 (Ce6) and the time-honored immunoadjuvant aluminum hydroxide into bovine serum albumin by albumin-based biomineralization as a novel nanosystem (Al-BSA-Ce6 NPs). After intravenous injection, the nanoparticles not only destroyed tumor cells effectively but also protected animals against tumor rechallenge and metastasis by strongly inducing a systemic anti-tumor immune response. Subsequent analysis demonstrated T cells accumulated in lymph nodes and infiltrated the tumor site, elevating levels of immune indicators including serum antibody, cytokine level and higher proportions of cytotoxic T cells and Th1 cells. These protective effects were not observed with commercially available alumina gels, or when the aluminum hydroxide in the nanoparticles was replaced with ferric hydroxide. Therefore, we present Al-BSA-Ce6 NPs as a novel and unique system for alumina adjuvants that serves as an effective approach for cancer therapy. Unlabelled Image • A nanoparticle system (Al-BSA-Ce6 NPs) synthesized by a biomineralization method for photo-immunotherapy against melanoma. • Unique immunological properties and therapeutic effect were confirmed by comparison with alumina gel and Fe-BSA-Ce6 NPs. • A simple synthesis method using only FDA approved excipients provides great potential for clinical translation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01683659
Volume :
322
Database :
Academic Search Index
Journal :
Journal of Controlled Release
Publication Type :
Academic Journal
Accession number :
143384032
Full Text :
https://doi.org/10.1016/j.jconrel.2020.03.045